バイオテクノロジーニュース
  • June 13 , 2019

    Following CAR-T pioneer¬s' footsteps, Tessa launches China JV in $120M deal

    These days just about every biotech serious about global development — and not just commercialization — has a Chi-na strategy. Tessa Therapeutics, a Baylor associated outfit based out of Singapore, is no exception.
    詳しく見る
  • January 28 , 2019

    Zai Lab nabs speedy China regulatory review for PARP drug Zejula

    Chinese regulatory officials are signaling that they’re ready to whisk Zejula through the regulatory process.
    詳しく見る
  • January 3 , 2019

    2019 M&A starts with a bang as BMS and Celgene agree $74bn merger

    The pairing will create a company with annual sales north of $34 billion, behind Pfizer, Novartis and Roche in terms of 2017 prescription drug sales and ahead of Merck & Co and Johnson & Johnson. There’s also plenty of scope for cost-cutting – the two companies think they can find $2.5 billion in “synergies” by 2022.
    詳しく見る
  • October 1 , 2018

    Three Emerging Positive Trends to Watch in China Opening Up Huge Long-term Market Opportunity

    Three positive developments in China have evolved recently that could benefit the development, regulatory, reimbursement and - perhaps just as importantly-investment framework for biopharma. While still early, the Chinese govt is shifting from a network mostly "closed" to US Biopharma towards a more "open" and pro-innovation stance for medicine that could th
    詳しく見る
このウェブサイトでは、お客様の利便性を高めるためにクッキーを使用しています。お客様がこれに同意しているものとしますが、ご希望であればオプトアウトすることができます。 さらに詳しく
お問い合わせはこちらからお願いします。 お問い合わせ